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Abstract
Background: Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven
strategies for the management of HIV. That approach was evaluated in the SMART trial thatreported anunexpected increaseof
cardiovascular events after treatment interruption (TI). Our goal was to evaluate fasting metabolic changes associated with
interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk.
Methodology: ACTG 5102 enrolled 47 HIV-1-infected subjects on stable ART, with ,200 HIV RNA copies/mL and CD4 cell
count $500 cells/mL. Subjects were randomly assigned to continue ART for 18 weeks with or without 3 cycles of interleukin-
2 (IL-2) (cycle=4.5 million IU sc BID x 5 days every 8 weeks). After 18 weeks ART was discontinued in all subjects until the
CD4 cell count dropped below 350 cells/mL. Glucose and lipid parameters were evaluated every 8 weeks initially and at
weeks 2, 4, 8 and every 8 weeks after TI. Immune activation was evaluated by flow-cytometry and soluble TNFR2 levels.
Principal Findings: By week 8 of TI, levels of total cholesterol (TC) (median (Q1, Q3) (20.73 (21.19, 20.18) mmol/L,
p,0.0001), LDL, HDL cholesterol (20.36(20.73,20.03)mmol/L, p=0.0007 and 20.05(20.26,0.03), p=0.0033, respectively)
and triglycerides decreased (20.40 (20.84, 0.07) mmol/L, p=0.005). However the TC/HDL ratio remained unchanged (20.09
(21.2, 0.5), p=0.2). Glucose and insulin levels did not change (p=0.6 and 0.8, respectively). After TI there was marked
increase in immune activation (CD8+/HLA-DR+/CD38+ cells, 34% (13, 43), p,0.0001) and soluble TNFR2 (1089 ng/L (2189,
1655), p=0.0008) coinciding with the rebound of HIV viremia.
Conclusions: Our data suggests that interrupting antiretroviral therapy does not reduce cardiovascular disease (CVD) risk, as
the improvements in lipid parameters are modest and overshadowed by the decreased HDL levels. Increased immune cell
activation and systemic inflammatory responses associated with recrudescent HIV viremia may provide a more cogent
explanation for the increased cardiovascular risk associated with treatment interruption and HIV infection.
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Introduction
The continuous use of antiretroviral therapy (ART) has been
associatedwithaseriesofmetaboliccomplications[1]thathavebeen
linked to increased cardiovascular risk. [2,3] Treatment associated
toxicities together with the costs, both economic and in quality of life
terms associated with ART led to the consideration of CD4 driven
strategies for the management of HIV infection. [4,5,6] Frequently
cited arguments in support of those strategies were the potential
beneficial metabolic effects of interrupting drug treatment and the
possible reduction of drug-related toxicities. However, the strategy is
not without risks, including recrudescent HIV viremia and HIV
diseaseprogression. The metabolic effects and overallcardiovascular
risk of treatment interruption have not been well defined.
An unexpected result of the recently discontinued SMART trial,
the largest study that evaluated CD4 driven therapy, was an
increase in frequency of cardiovascular events in the drug
conservation arm. [7]
Although hyperlipidemia is clearly been linked to the develop-
ment of atherosclerosis, only recently has the critical role of
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e2021inflammatory mechanisms in the initiation, progression and acute
decompensation of the atheromatous plaque been appreciated.
[8,9,10]. A wide range of acute and chronic infections have been
associated with persistent inflammation which have been hypoth-
esized to accelerate atherosclerosis [11,12]. Untreated HIV
infection is characterized by increased levels of proinflamatory
cytokines TNF-alpha[13] and IL-6 and by increased expression of
adhesion molecules VCAM-1, ICAM-1 and von Willebrand
factor, factors identified to be important in the pathogenesis of
atherosclerosis[14]. Fully suppressive ART reverses these abnor-
malities [14] , and improves endothelial function, independently of
the regimen selected. [15]
Antiretroviral treatment interruption (TI) in chronically sup-
pressed individuals represents a unique situation because it links
the acute metabolic changes associated with the discontinuation of
ART with acute changes in the systemic degree of inflammation
associated with reinitiating HIV replication. Individuals who
discontinue ART will predictably go from a state of relatively low
systemic inflammation (fully suppressed HIV viral replication) to a
state of high inflammation, coinciding with the increase in HIV
viremia that tends to occur approximately 2 weeks after
discontinuation of therapy. [16,17]
The goal of this analysis was to evaluate the metabolic changes
associated with the discontinuation of ART and the changes in
immune activation markers to identify changes in cardiovascular
risk in this situation. We used the setting of a prospective
randomized trial, ACTG 5102, [17] that evaluated the utility of
interleukin-2 in delaying the re-initiation of ART as part of a CD4
driven strategy in the management of HIV infected individuals.
Methods
Subjects
This study is a sub-study of ACTG study 5102. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1. Details
summarizing ACTG A5102 have been recently published. [17]
ACTG 5102 enrolled HIV-1-infected adults receiving stable ART,
who were virologically fully suppressed (,200 HIV RNA copies/
mm
3) for at least three months at the time of enrollment and had a
CD4 cell count $500 cells/mm
3. The study was approved by the
IRB of all participant institutions and all subjects provided written
informed consent.
Intervention
47 subjects were then randomly assigned to continue ART for
18 weeks (Step 1) with (ARM A) or without (ARM B) 3 cycles of
IL-2 (cycle=4.5 million IU sc BID x 5 days every 8 weeks). After
18 weeks ART was discontinued in all subjects (Step 2). Subjects
were followed monthly with monitoring of their CD4+ T-cell
counts and plasma HIV-1 RNA levels. ART was restarted when
the CD4+ cells reached a confirmed level of ,350 cells/mL. At
that point ART was restarted for 6 months and if the CD4+ cells
again reached $500 cells/mL, the cycle was repeated. In this
analysis we report only the results of the first treatment
interruption. Figure 1 shows a consort diagram of this study.
Medications
Recombinant human interleukin-2 (ProleukinH) was provided
by Chiron Corporation. ART were provided by prescription
through the subject’s physician. No changes of antiretroviral
regimen were allowed during Step 1. There were protocol defined
recommendations for the management of IL-2 toxicities.
Laboratory
CD4+ and CD8+ T-cell counts were measured using standard
flow cytometry techniques at the same local ACTG-certified flow
laboratory throughout the study (every 4 weeks during while on
ART and at weeks 0,2,4,8, and every 4 weeks thereafter on the
treatment interruption phase). HIV viral load was determined at
weeks 0, 8 and 16 of Step 1 and weeks 2, 4, 6, 8, 16 and every
8 weeks thereafter in Step 2 using the UltraSensitive Roche
Amplicor HIV-1 Monitor
TM assay in a central laboratory. Fasting
metabolic testing (glucose, insulin, total, calculated LDL and HDL
cholesterol and triglycerides) were analyzed at the same time
points (weeks 0, 2, 4, 6, 8, 16 and every 8 weeks) at each
participating site laboratory. The baseline for Step 1 analysis were
the values at randomization into the study. Baseline for changes
after treatment interruption were the values obtained immediately
before treatment interruption (week 0 of step 2). The number and
percentage of CD8+ cells expressing activation markers (CD38+/
HLA-DR+) were measured at entry and at week 16 of Step 1 while
the participant was receiving ART and at weeks 2, 4, and 8 of Step
2 (TI) using 3 color flow cytometry following ACTG consensus
methodology
16. Serum TNF Receptor alpha 2 was measured
before TI and 24 weeks after discontinuation of ART. The
metabolic effects of IL-2 had not been described. If there were no
changes in the metabolic parameters during the first phase of the
study, we planned to combine both arms for the purpose of this
analysis.
Statistical analysis
Summary statistics for continuous variables were presented as
median (first quartile, third quartile). Comparison between
treatment arms was carried out using a Wilcoxon Rank Sum
Test for ordinal valued outcomes, and a Fisher’s Exact Test or
Pearson’s Chi-square Test for categorical factors. Within each
arm, a Wilcoxon Signed Rank Test was used to assess differences
over time. Spearman’s rank correlation was used to measure the
relationship between immunologic and metabolic markers. The
level of significance used was 0.05. These results are not adjusted
for multiple testing and are therefore exploratory. Laboratory
results from participants were censored after reinitiating antiret-
roviral treatment.
Figure 1. Consort diagram. All patients were included in the analysis
and censored after the re-initiation of antiretroviral therapy during Step 2.
doi:10.1371/journal.pone.0002021.g001
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The results of the primary analysis of the study have been
recently published. [17] In summary, three cycles of interleukin-2
given during the first 18 weeks of the study, delayed the initial
decay of CD4 T cells after TI, but this benefit was lost by
72 weeks. Twenty-one of the study subjects were on a protease
inhibitor based regimen.
Baseline and week 16 changes from baseline in fasting total
cholesterol, triglycerides, HDL cholesterol and non-HDL choles-
terol, fasting glucose and insulin were comparable between the
study arms (Table 1). Although there were statistically marginally
significant differences observed with respect to week 16 cholesterol
and non HDL cholesterol (p=0.04 and p=0.03, not corrected for
multiple comparisons), within each arm there were no significant
changes from baseline. Because of these results the metabolic
parameters from subjects in both arms after interruption were
combined.
The baseline values for subsequent analysis are the ones
immediatelybeforetreatment interruption.After thediscontinuation
of ART there was a rapid decrease of the concentrations of total
cholesterol.Byweek8ofTI,levelsoftotalcholesterol(TC)decreased
(median(Q1, Q3)=20.73 (21.19, 20.18) mmol/L, p,0.0001) as
well as triglycerides (20.40 (20.84, 0.07) mmol/L, p=0.005). LDL
and HDL cholesterol also decreased (20.36(20.73,20.03)mmol/L,
p=0.0007 and 20.05(20.26,0.03), p=0.0033, respectively)
(Figure 2). These decreases persisted for the duration of the follow
up. All of these changes were evident before the return of detectable
HIV plasma RNA, defined by HIV-1 RNA .500 copies/mL.
Rebounding HIV-1 RNA values.500copies/mLwereidentifiedat
2 weeks in 20 of 45, after 4 weeks in 35 of 45, and for 45 of 45 by
week 8 of treatment interruption. This suggests that lipid changes
were mediated directly by the discontinuation of ART and not by
HIV replication itself. After 48 weeks off therapy there was a
continuing decrease in HDL levels and a continuing increase in
triglyceride levels.
The total cholesterol to HDL cholesterol ratio decreased slightly
during the first 4 weeks (20.5,IQR 21.2–0.06, p=0.001) after TI
but returned to baseline by week 8 (20.09 (IQR 21.2, 0.5),
p=0.2) and remained unchanged afterwards due to the marked
decreases in HDL cholesterol (Figure 3A).
After interruption the percentage of individuals with HDL
cholesterol less than 40 mg/mL (1.04 mmol/L) went from 53%
before discontinuation to 76% after 48 weeks. After the discon-
tinuation of ART there were no significant changes in either the
fasting glucose or insulin levels.
During Step 1 (continuous ART), there was no significant
difference within the arms in the change from baseline in the
percentage of CD8+ T-cells expressing activation markers (HLA-
DR and CD38). The median baseline absolute number of CD8+/
HLA DR+ cells were 220 in the IL-2 arm and 204 cells per mm
3
in the no-IL2 arm, at the end of step 1 they were 267 and 231 per
mm
3 respectively, p=0.55). There was no significant difference
within the arms in the change from baseline in the percentage of
CD8+ T-cells expressing activation markers (HLA-DR and
CD38). Nevertheless, during Step 1 subjects in the IL-2 group
(median change 21%, IQR: 23 to 0%) tended to experience a
decrease in the percent of activated CD8+ T-cells while those not
receiving IL-2 tended to experience an increase (median change
1%, IQR: 21 to 5%; p=0.03, Wilcoxon test for the difference
between arms).
As expected, after the discontinuation of treatment there was a
significant increase in cellular and soluble activation markers in all
participants. The increase in CD8+ T-cell activation was faster
among individuals that received ART alone during Step 1. These
patients experienced a significant increase in activation at week 2
of Step 2 (median increase 3%, vs 0% p=0.01), while those not
receiving IL-2 did not experience a significant increase in
activation until week 4 (median increase 20%, p=0.0002). By
eight weeks after ART discontinuation the median increase in
activated CD8+ cells was similar between groups (median increase
32% and 42% for IL-2 and non-IL-2 recipients, p=0.17). After
8 weeks of TI the percentage of activated CD8 cells in the whole
group (HLA-DR+ and CD38+ positive) had increased a median of
34% (IQR 13–43%, Wilcoxon signed rank p,0.0001). The levels
of TNF receptor alfa II increased approximately by 30% after
24 weeks after the discontinuation of ART (1089 ng/L (2189,
1655), p=0.0008) (Figure 3).
Table 1. Summary of changes in lipid and glucose parameters during Step 1 of the trial, when participants were receiving ART
with or without IL2.
ART+IL-2 ART alone
Median (IQR) Median IQR p value
Cholesterol W 0 5.6 (5.4–6.1) 5.3 (4.6–5.7) 0.19
(mmol/L) W 16 5.8 (5.3–6.5) 5.0 (4.6–5.9) 0.04
Triglycerides W 0 2.4 (1.9–3.3) 1.8 (1.4–2.2) 0.17
(mmol/L) W 16 2.3 (1.5–3.4) 1.7 (1.3–2.5) 0.29
HDL W 0 1.0 (1.0–1.2) 1.1 (0.9–1.3) 0.45
(mmol/L) W 16 1.1 (1.0–1.2) 1.0 (0.8–1.3) 0.73
Non-HDL W 0 4.6 (4.2–5.0) 4.1 (3.4–4.5) 0.07
(mmol/L) W 16 4.8 (4.2–5.6) 3.9 (3.5–4.8) 0.03
Glucose W 0 5.1 (4.6–5.2) 4.9 (4.4–5.2) 0.70
(mmol/L) W 16 5.0 (4.6–5.5) 5.0 (4.6–5.4) 0.93
Insulin W 0 71 (49–104) 65 (35–90) 0.38
(pmol/L) W 16 57 (42–110) 61 (35–79) 0.50
The p value represents comparisons between groups (Wilcoxon rank sum). There were no significant differences in the change from baseline within or between groups,
so both groups were merged for the Step 2 analysis.
doi:10.1371/journal.pone.0002021.t001
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lipid or glucose parameters and the changes in immune activation
markers or viral markers during the first weeks of follow up (data
not shown).
Discussion
Our study shows the metabolic effects of discontinuing ART.
They generally appear to be the reverse pattern of the sequence of
changes observed after the initiation of ART. [18] The lack of
significant changes in glucose and insulin suggests that the effect of
ART on those parameters is limited. That observation is in sharp
contrast with the prompt changes in lipid levels seen upon TI. The
rapid changes of lipid levels indicates that these effects are due
directly to the medications, and most likely are not mediated by
changes in body composition which require a lengthier period of
time. It is also unlikely that these initial lipoprotein changes are
related to HIV replication, as they occurred before the return of
HIV viremia.
Over the long term, although the decrease in total and LDL
cholesterol might be associated with a decreased cardiovascular
risk, those benefits may be offset by the marked decrease in HDL
cholesterol observed. Total/HDL cholesterol ratio may more
accurately capture the overall cardiac risk as compared to other
individual lipoprotein measurements [19]. In fact the total
cholesterol to HDL ratio, although improved during the first four
weeks after interruption, returned to baseline by 8 weeks. In
addition, the initial benefits in triglycerides levels tended to
become less apparent as the duration of the TI increased. Our
interpretation of these late lipid changes observed after 24–
48 weeks of TI is that they represent the adverse metabolic effects
of unabated HIV replication rather than any residual effect of
ART. These changes are similar to the lipid effects seen in acute
and chronic HIV infection in the absence of treatment[20]. The
lipid abnormalities could be cytokine driven [21] or mediated
directly by HIV replication [22,23] or both. The net effect of the
observed lipid changes would predict little if any improvement in
the cardiovascular risk after the discontinuation of ART.
Following treatment interruption there is a prompt and obvious
increase in cellular activation, which could negate any potential
cardiovascular benefits of TI. The simultaneous combination of
these two phenomena (modest decreases in lipids with no net
cardiovascular benefit and significant pro-inflammatory changes)
could partially explain the increase in cardiovascular events
observed in the SMART trial and other studies after the
discontinuation of ART. [7,24] Many patients on ART have
been in a state of pro-atherogenic dyslipidemia for years that could
have lead to the development of plaques. The sudden change to a
more pro-inflammatory state induced by the abrupt return of HIV
replication could result in an increased platelet adhesion and
inflammatory cell migration into unstable plaque. Many studies
have shown that both such local and systemic inflammation plays a
central role in the development of atherosclerosis [9].
Our study may also provide some insight explaining two
apparently discordant large data sets regarding cardiovascular risk
and HIV infection: the one from the Veterans Administration
study conducted by Bozzete et al. [25]and the DAD cohort study.
[2,3] In the first study, there was an apparent decreased incidence
of cardiovascular events among patients with HIV infection
starting therapy in the mid to late 90’s. These could be interpreted
as improvement in cardiovascular outcomes secondary to the
decrease cellular activation associated with the initiation of ART,
as the majority of the patients in that cohort were initiating potent
ART during the observation period. On the other hand, in the
DAD cohort more than 80% of the patients at the time of
enrollment (1999–2001) were already receiving potent ART for a
median of almost 2 years, with most individuals having undetect-
able HIV-1 RNA viral loads and a state of low cellular activation.
In this state, traditional cardiovascular risk factors including
hyperlipidemia become more important and may be responsible
for the modest rise in cardiovascular events observed with
increased duration of treatment.
Our study has limitations that are important to point out; first it
is a pilot study has a relatively small sample size, especially when
compared to the more than 5,000 participants in the SMART
trial. However our sample has enough power to identify the
immediate effects of treatment discontinuation, both in lipid
parameters and immune activation, our stated goals. Second the
evaluation of immune activation is relatively crude and completed
in a number of limited time points; however the results are
consistent with what is known about ongoing HIV viremia. The
lost to follow up rate was comparable to antiretroviral treatment
trials of similar duration, with only 10 participants dropping out of
the study (21%).
Our results suggest that TI would not reduce CVD risk, as any
improvements in lipid parameters are modest and overshadowed
by the decreased HDL levels and the increased immune cell
Figure 2. Glucose and Lipid Metabolism During Prolonged TI
(median % change from baseline and IQR).
doi:10.1371/journal.pone.0002021.g002
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e2021Figure 3. Total cholesterol to HDL ratio changes overtime after treatment interruption (median change and IQR). Percentage change
of CD8+/HLA-DR+/CD38+ cells after TI. (median and IQR) Absolute change in soluble serum TNR II levels (median and IQR) Individuals were censored
after reinitiating antiretroviral therapy, thus the decreasing N in the figures.
doi:10.1371/journal.pone.0002021.g003
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returning HIV viremia. These effects could put the patients at a
greater cardiovascular risk than when they were receiving
antiretroviral treatment. Decreasing immune activation after TI
and potentially among patients with ongoing viral replication
could mitigate the cardiovascular morbidity and mortality
associated with HIV viremia. Prospective trials of anti-inflamma-
tory interventions to mitigate the risk of acute cardiovascular
events in cases where treatment must be interrupted are
warranted. Treatment interruptions provide a setting in which
the relationship between viremia, immune activation and humoral
inflammatory markers can be accurately assessed.
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